SCHEMBL17959009

SCHEMBL17959009

O=C(NO)c1ccc2c(c1)OCCCN(c1ccccc1)C2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 7/20 0.47
▸ HDAC1 Q13547 1/20 0.47
▸ RAB9A P51151 6/20 0.46
▸ NPC1 O15118 6/20 0.46
▸ LMNA P02545 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ KMT2A Q03164 3/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ HPGD P15428 2/20 0.43
▸ MAPK1 P28482 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.42
▸ PKM P14618 2/20 0.41
▸ NFKB1 P19838 1/20 0.41
▸ MAOB P27338 1/20 0.41
▸ NFKB2 Q00653 1/20 0.41
▸ RELA Q04206 1/20 0.41
▸ PAX8 Q06710 1/20 0.41
▸ KLF5 Q13887 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17957663 0.93 KMT2A (0.44) HDAC6HDAC1RAB9ANPC1LMNA
SCHEMBL17959067 0.91 HDAC6 (0.47) HDAC6HDAC1RAB9ANPC1LMNA
SCHEMBL17959003 0.84 HDAC6 (0.60) HDAC6HDAC1RAB9ANPC1LMNA
SCHEMBL17958994 0.82 HDAC6 (0.47) HDAC6HDAC1RAB9ANPC1LMNA
SCHEMBL20912352 0.81 KCNQ2 (0.51) HDAC6RAB9ANPC1LMNAMAPT
SCHEMBL17957676 0.81 MAPT (0.45) HDAC6HDAC1RAB9ANPC1LMNA
SCHEMBL17957700 0.81 NPC1 (0.47) HDAC6HDAC1RAB9ANPC1LMNA
SCHEMBL17959056 0.81 HDAC6 (0.57) HDAC6HDAC1RAB9ANPC1HPGD
SCHEMBL20912072 0.81 KCNQ2 (0.48) HDAC6HDAC1RAB9ANPC1LMNA
SCHEMBL17959052 0.81 NPC1 (0.54) HDAC6HDAC1RAB9ANPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10183934-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors FORMA THERAPEUTICS, INC. (US) 2019-01-22 — — US claimed
WO-2016126726-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC6 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2016-08-11 — — WO claimed
US-20160221997-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS Valo Health, LLC 2016-08-04 — — US claimed
US-12304904-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors VALO HEALTH, INC. (US) 2025-05-20 — — US disclosed
US-20230357216-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS Valo Health, LLC 2023-11-09 — — US disclosed
US-11702412-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors VALO HEALTH, INC. (US) 2023-07-18 — — US disclosed
US-20210206755-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS VALO HEALTH, INC. 2021-07-08 — — US disclosed
US-10870645-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors VALO EARLY DISCOVERY, INC. (US) 2020-12-22 — — US disclosed
US-20190345149-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS Valo Health, LLC 2019-11-14 — — US disclosed
US-10407418-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors FORMA THERAPEUTICS, INC. (US) 2019-09-10 — — US disclosed
US-20190092762-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS FORMA THERAPEUTICS, INC. (US) 2019-03-28 — — US disclosed
US-10183934-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors FORMA THERAPEUTICS, INC. (US) 2019-01-22 — — US disclosed
WO-2016126726-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC6 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2016-08-11 — — WO disclosed
US-20160221997-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS Valo Health, LLC 2016-08-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357216-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS HDAC1, HDAC2, HDAC4 HDAC6 7/4885HDAC1 1/4885RAB9A 3329/4885
US-10870645-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors HDAC1, HDAC2, HDAC4 HDAC6 7/4885HDAC1 1/4885RAB9A 3329/4885
US-10407418-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors HDAC1, HDAC2, HDAC4 HDAC6 7/4885HDAC1 1/4885RAB9A 3329/4885
US-20160221997-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS HDAC1, HDAC2, HDAC4 HDAC6 7/4885HDAC1 1/4885RAB9A 3329/4885
US-10183934-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors HDAC1, HDAC2, HDAC4 HDAC6 7/4885HDAC1 1/4885RAB9A 3329/4885
US-12304904-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors HDAC1, HDAC2, HDAC4 HDAC6 7/4885HDAC1 1/4885RAB9A 3329/4885
US-20190092762-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS HDAC1, HDAC2, HDAC4 HDAC6 7/4885HDAC1 1/4885RAB9A 3329/4885
US-11702412-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors HDAC1, HDAC2, HDAC4 HDAC6 7/4885HDAC1 1/4885RAB9A 3329/4885
US-20190345149-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS HDAC1, HDAC2, HDAC4 HDAC6 7/4885HDAC1 1/4885RAB9A 3329/4885
US-20210206755-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS HDAC1, HDAC2, HDAC4 HDAC6 7/4885HDAC1 1/4885RAB9A 3329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback